Get the Stockscreener App
827.02
1.30%
10.65
After Hours:
827.02
Argen X Se Adr stock is traded at $827.02, with a volume of 415.20K.
It is up +1.30% in the last 24 hours and down -2.94% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$816.37
Open:
$820.29
24h Volume:
415.20K
Relative Volume:
1.16
Market Cap:
$51.18B
Revenue:
$3.06B
Net Income/Loss:
$1.28B
P/E Ratio:
42.04
EPS:
19.6719
Net Cash Flow:
$447.35M
1W Performance:
+1.69%
1M Performance:
-2.94%
6M Performance:
+44.78%
1Y Performance:
+29.25%
1-Day Range:
$816.29
$827.60
1-Week Range:
$781.07
$827.60
52-Week Range:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-15-25 | Resumed | Truist | Buy |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Jefferies Keeps Their Buy Rating on Argenx Se (ARGX) - The Globe and Mail
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Argenx shares rise as FDA reviews Vyvgart for broader use By Investing.com - Investing.com South Africa
Argenx shares rise as FDA reviews Vyvgart for broader use - Investing.com
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG - Chartmill
William Blair reiterates Outperform rating on argenx stock - Investing.com
Argenx shares slip as Q4 results come in broadly in line - Investing.com
Wells Fargo Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
argenx SE stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
Argenx stock holds steady as TD Cowen reiterates Buy rating By Investing.com - Investing.com South Africa
Argenx stock holds steady as TD Cowen reiterates Buy rating - Investing.com
Argenx founder Tim Hauwermeiren to step down as CEO; Karen Massey named successor - Investing.com India
argenx Announces Leadership Transition Marking Next Evolution of Growth - Sahm
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx SE Sponsored ADR (ARGX) Stock Price History & Data - Traders Union
BofA Securities raises argenx stock price target to $1,006 on strong Vyvgart outlook - Investing.com India
Baird downgrades argenx stock rating to Neutral on valuation concerns By Investing.com - Investing.com South Africa
Baird downgrades argenx stock rating to Neutral on valuation concerns - Investing.com
Argenx stock price target raised to $925 from $860 at RBC Capital By Investing.com - Investing.com South Africa
Argenx stock price target raised to $925 from $860 at RBC Capital - Investing.com
Argenx stock rating maintained at Buy by BofA despite TED trial failure - Investing.com South Africa
Jefferies maintains Buy rating on argenx stock despite failed TED trial - Investing.com
argenx stock rating reiterated at Buy by Guggenheim despite TED study halt - Investing.com South Africa
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Sahm
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
argenx stock tumbles after discontinuing thyroid eye disease studies - Investing.com
Argenx, Navan And 3 Stocks To Watch Heading Into Monday - Sahm
Immunovant: "Buy" On Competitive Batoclimab Landscape And IMVT-1402 Advancement (IMVT) - Seeking Alpha
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance By Investing.com - Investing.com South Africa
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance - Investing.com India
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth By Investing.com - Investing.com South Africa
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth - Investing.com India
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argenx NV ADR stock hits all-time high at $934.62 - Investing.com India
Argenx NV ADR stock hits all-time high at $934.62 By Investing.com - Investing.com South Africa
ClearBridge International Growth ADR ESG Portfolios Q3 2025 Commentary - Seeking Alpha
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):